ClinicalTrials.gg
CompletedNCT00441441Updated Dec 16, 2016Results posted

A 12-Week Study To Assess The Safety Of Fluticasone Propionate/Salmeterol 100/50 Hydrofluoroalkane (HFA) Versus Fluticasone Propionate 100 HFA In Children With Asthma

A Phase 3 interventional study of fluticasone propionate and fluticasone propionate/salmeterol in Asthma, sponsored by GlaxoSmithKline. Completed at 55 sites in 13 countries. Open to participants aged 4 Years to 11 Years. Per ClinicalTrials.gov, last updated 2016-12-16.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
351
Allocation
Randomized
Ages
4 Years to 11 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 147 studies testing fluticasone in Asthma — 1 open to participants now, 4 under way, 2 of them phase 3. Fluticasone · Asthma.

Enrollment
45th of 146
351 · median 100
Started
2007
with 17 others
Phase 3
35 of 147
none open now
Registered
29th of 147
by date
Lead sponsor
69 of 147
GlaxoSmithKline

Among the 147 studies testing fluticasone in Asthma, this one is the 45th largest by enrollment of the 146 interventional ones that give a count, is one of 18 that started in 2007, is one of 35 in phase 3, and was the 29th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

1 of the 147 studies testing fluticasone in Asthma is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About fluticasone

Fluticasone: first FDA approval 1990 (CUTIVATE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.

This study: 4 Years to 11 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 147 studies testing fluticasone in Asthma, or all of them as a file.
02

Study summary

This study is to assess the safety of an investigational drug in children 4 to 11 years of age who have asthma. The subjects will attend 7 clinic visits, of which up to 3 will be in the morning, and have lung function tests performed.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • asthma
  • fluticasone propionate
  • children
  • fluticasone propionate/salmeterol
04

Who can participate

Ages eligible
4 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must have asthma.
  • Must be currently taking an inhaled .
  • Must be able to attend 7 clinic visits, of which up to 3 will be in the morning, and have lung function tests that are at least 60% of normal (AM or PEF).
  • Have a historical or current FEV1 or PEF reversibility of >=12%.

Exclusion criteria

Exclusion criteria:

  • Has ever had life-threatening asthma (for example respiratory arrest, mechanical ventilation).
  • Has a current ear or respiratory tract infection.
  • Has ever had any other major illnesses (such as cystic fibrosis, heart problems, tuberculosis).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
351 participants (actual)

Study arms

  • Experimental
    Fluticasone propionate/salmeterol 100/50 HFA

    Fluticasone propionate/salmeterol 100/50 HFA (2 inhalations of 50/25mcg), twice daily (strengths are ex-valve) and a placebo HFA inhaler matching the fluticasone propionate 100mcg HFA inhaler (2 inhalations) twice daily

    Drug: fluticasone propionate/salmeterol

  • Experimental
    Fluticasone propionate 100mcg HFA

    Fluticasone propionate 100mcg HFA (2 inhalations of 50mcg), twice daily (strengths are ex-valve) and a placebo HFA inhaler matching the fluticasone propionate/salmeterol 100/50 HFA inhaler (2 inhalations ) twice daily

    Drug: fluticasone propionate

Interventions

06

What researchers measure

Primary outcomes

  1. Possible Drug-Related Adverse Events

    Adverse Events reported by the Investigator and judged by the Investigator to be possibly related to study drug, categorized by the Medical Dictionary for Regulatory Activities (MeDRA), were reported. ECG, electrocardiogram. QTc (corrected QT interval) and QT represent intervals on an ECG.

    Time frame: Treatment period (weeks 1-12) and Post Treatment (≥1 day after last time study drug)

  2. Investigator Evaluations of Electrocardiogram (ECG) Results

    ECGs were transmitted to an independent cardiologist who was responsible for providing interpretation of the ECG as either normal or abnormal (based on personal assessment). The investigator was then responsible for determining the clinical significance of the abnormal ECG in the context of the participants' history and clinical presentation. An abnormal, clinically significant ECG included, but was not limited to: prolonged QT interval, ischemic changes, ventricular hypertrophy, intraventricular conduction abnormalities, and clinically significant arrhythmias. PD, premature discontinuation.

    Time frame: Baseline and Week 12

  3. Clinically Significant Unfavorable ECGs at Week 12

    Post-randomization ECGs categorized by the primary investigator as no change, significant change (favorable), significant change (unfavorable) from the ECG performed at Visit 1 (Baseline) are presented. Significant change (favorable) includes any ECG that improved from baseline, whereas significant change (unfavorable) includes any ECG that worsened from baseline. Clinical significance is determined by the primary investigator.

    Time frame: Baseline, Week 12

  4. ECG Measures - Heart Rate

    The range of heart rates for this study was between 49-144 beats per minute

    Time frame: Baseline and Week 12

  5. ECG Measures - QT Interval

    Fridericia's formula QTc interval=QT interval/cubed root of the R-R interval. The Bazett's formula QTc=QT/squared root of the R-R interval.

    Time frame: Baseline and Week 12

  6. Cardiovascular Adverse Events Reported During Treatment Period

    Cardiovascular Adverse Events, as categorized by the Medical Dictionary for Regulatory Activities (MeDRA), reported during Treatment Period. The Adverse Events were identified in any ECG interpretation by a central reader (Cardiologist) for any ECG obtained after the first treatment dose and were then reported by the Primary Investigator as an Adverse Event. Please see the category titles for a list of candidate cardiovascular adverse events.

    Time frame: 12-Week Treatment Period

  7. Cardiovascular Adverse Events Reported During the Post-Treatment Period

    Cardiovascular Adverse Events, as categorized by the Medical Dictionary for Regulatory Activities (MeDRA), reported during Post-treatment period, defined as 1 day after last dose of study drug. The Adverse Events were identified in any ECG interpretation by a central reader (Cardiologist) for any ECG obtained after the first treatment dose and were then reported by the Primary Investigator as an Adverse Event.

    Time frame: 5 Days after Week 12

  8. Asthma Exacerbations: Worsening of Asthma Requiring Emergency Intervention, Hospitalization, or Treatment With Asthma Medications Prohibited by the Protocols

    The Primary Investigator determined the severity of the exacerbation based on the participant's clinical presentation and the investigator's understanding of the disease, the participant, and his or her clinical experiences. The severity of the exacerbation was not defined in the protocol. Mild: Usually treated at home. Prompt relief with inhaled short-acting beta2 agonist. Possible short course of oral systemic corticosteroids. Moderate: Usually requires office or emergency department visit. Relief with frequent inhaled short-acting beta2 agonist. Oral systemic corticosteroids; some symptoms last for 1-2 days after treatment begins. Severe: Usually requires emergency department visit and likely hospitalization. Partial relief with frequent inhaled short-acting beta2 agonist. Oral systemic corticosteroids; some symptoms last for more than 3 days after treatment begins. Adjunctive therapies are helpful.

    Time frame: Treatment period (weeks 1-12)

  9. Number of Participants With the Indicated Levels of 24-hour Urinary Cortisol Excretion

    "Abnormal high cortisol excretion" and "Abnormal low cortisol excretion" are defined as above the upper limit of normal and below the lower limit of normal, respectively. The normal range for cortisol levels vary by age and gender. An abnormality is defined as a value of 24-hour urinary cortisol excretion that is outside the normal range. The normal range for 24-hour urinary cortisol excretion was provided by the central laboratory.

    Time frame: Baseline and week 12

  10. Geometric Mean Values of 24-hour Urinary Cortisol Excretion at Baseline and Week 12

    Normal range for Cortisol levels vary by age and gender. Geometric mean is the product of the values taken to the Nth root, where N is the number of values in the set of values.

    Time frame: Baseline and Week 12

  11. Geometric Mean Ratio for Week12:Baseline for 24-hour Urinary Cortisol Excretion

    Normal range for Cortisol levels vary by age and gender. The data provided are a direct calculation of the Week 12 geometric mean divided by the baseline value, nanomoles per 24 hours (nmol/24 hrs).

    Time frame: Baseline and Week 12

  12. Number of Participants With the Indicated Levels of 24 Hour Urinary Cortisol Excretion by Spacer Use

    AeroChamber Plus spacers were provided for participants who demonstrated the inability to coordinate the use of an Meter Dose Inhaler at Visit 1. AeroChamber Plus spacer delivers 22% more medication than the original AeroChamber and is available in three mask sizes and without a mask. "Abnormal high cortisol excretion" and "Abnormal low cortisol excretion" are defined as above the upper limit of normal and below the lower limit of normal, respectively. An abnormality is defined as a value of 24-hour urinary cortisol excretion that is outside the normal range. The normal range for 24-hour urinary cortisol excretion was provided by the central laboratory.

    Time frame: Baseline and Week 12

  13. Geometric Mean Values of 24 Hour Urinary Cortisol Excretion by Spacer Use at Baseline and Week 12

    AeroChamber Plus spacers were provided for participants who demonstrated the inability to coordinate the use of an Meter Dose Inhaler at Visit 1. AeroChamber Plus spacer delivers 22% more medication than the original AeroChamber and is available in three mask sizes and without a mask. Geometric mean is the product of the values taken to the Nth root, where N is the number of values in the set of values.

    Time frame: Baseline and Week 12

  14. Geometric Mean Ratio for Week12: Baseline for 24 Hour Urinary Cortisol Excretion by Spacer Use

    AeroChamber Plus spacers were provided for participants who demonstrated the inability to coordinate the use of an Meter Dose Inhaler at Visit 1. AeroChamber Plus spacer delivers 22% more medication than the original AeroChamber and is available in three mask sizes and without a mask. The data provided are a direct calculation of the Week 12 geometric mean divided by the baseline value, nanomoles per 24 hours (nmol/24 hrs).

    Time frame: Baseline and Week 12

Secondary outcomes

  1. Clinic Morning (AM) Forced Expiratory Volume in Participants 6-11 Years

    FEV1 (Forced Expiratory Volume in 1 second) is the volume of air that can be forced out in one second, after taking a deep breath. FEV1 is measured using a spirometer and obtaining "best effort" from 3 to 8 measurements. Week 12 is the measure taken at Week 12.

    Time frame: Baseline and week 12

  2. AM Peak Expiratory Flow

    The peak expiratory flow (PEF) rate measures how fast a person can exhale air. It is used to compare to normal flow rates to predict obstruction and disease. The average PEF for a child or adolescent whose height is 43 inches is 147 Liters/minute (L/min), whose height is 66 inches is 454 L/min. Triplicate measurements taken for the best effort recorded.

    Time frame: Baseline and 12-Week Treatment Period

  3. Asthma Symptom Scores

    Each morning prior dosing or PEF, self-scored based on past 24 hours: 0=No symptoms, 1=Symptoms for one short period, 2=Symptoms for two or more short periods, 3=Frequent Symptoms which did not affect activities of daily living (ADL), 4=Frequent.

    Time frame: Baseline and 12-Week Treatment Period

  4. Percentage of Symptom Free Days

    Percentage of number of days without asthma symptoms based on Asthma Symptom Scores. Each morning prior to dosing or PEF, asthma symptoms were self-scored based on the past 24 hours: 0=no symptoms, 1=symptoms for one short period, 2=symptoms for two or more short periods, 3=frequent symptoms that did not affect activities of daily living (ADL), 4=frequent .

    Time frame: Baseline and 12-Week Treatment Period

  5. Albuterol Use

    Albuterol inhalation aerosol was used as a rescue or prophylactic and recorded daily by subject or caregiver. The number of puffs of albuterol over the previous 24 hour period prior to dosing was recorded.

    Time frame: Baseline and 12-Week Treatment Period

  6. Percent of Albuterol-free Days

    Percentage of days when Albuterol use was unnecessary based on daily record and symptom free days.

    Time frame: Baseline and 12-Week Treatment Period

07

Results

Posted Sep 23, 2010
Limitations and caveats
A post-hoc evaluation confirmed that no clinically relevant ECG abnormalities were present. Differences in the primary and post-hoc analyses were associated with variation in the method of ECG interpretation and are not fully interpretable.

Participant flow

A total of 351 participants were enrolled in the study. However, only 350 of these 351 participants comprised the Intent-to-Treat Population, defined as all participants who were randomly assigned to treatment and received \>=1 dose of Double-Blind study treatment.

Participant flow — Overall Study
MilestoneFluticasone Propionate/Salmeterol Hydrofluoroalkane (HFA)Fluticasone Propionate HFA
Started173177
Completed162163
Not completed1114
Withdrew: Adverse event21
Withdrew: Protocol violation46
Withdrew: Exacerbation of asthma12
Withdrew: Withdrawal by subject12
Withdrew: Other33

Outcome measures

PrimaryPossible Drug-Related Adverse Events

Adverse Events reported by the Investigator and judged by the Investigator to be possibly related to study drug, categorized by the Medical Dictionary for Regulatory Activities (MeDRA), were reported. ECG, electrocardiogram. QTc (corrected QT interval) and QT represent intervals on an ECG.

Time frame:
Treatment period (weeks 1-12) and Post Treatment (≥1 day after last time study drug)
Reported as:
Number · participants
Possible Drug-Related Adverse Events
participantsFluticasone Propionate/Salmeterol HFAFluticasone Propionate HFA
Participants with any drug-related event1316
Investigations - ECG QTc interval prolonged94
Investigations - QT interval prolonged02
Investigations - ECG QT borderline prolonged10
Investigations - ECG QT interval abnormal10
Cardiac - Defect conduction intraventricular27
Cardiac - Conduction disorder11
Cardiac - Sinus tachycardia10
Cardiac - Supraventricular ectopics01
Infections/Infestations - Oral candidiasis01
Infections/Infest - Oropharyngeal candidiasis01
Respiratory/thoracic/mediastinal - Dysphonia20
PrimaryInvestigator Evaluations of Electrocardiogram (ECG) Results

ECGs were transmitted to an independent cardiologist who was responsible for providing interpretation of the ECG as either normal or abnormal (based on personal assessment). The investigator was then responsible for determining the clinical significance of the abnormal ECG in the context of the participants' history and clinical presentation. An abnormal, clinically significant ECG included, but was not limited to: prolonged QT interval, ischemic changes, ventricular hypertrophy, intraventricular conduction abnormalities, and clinically significant arrhythmias. PD, premature discontinuation.

Time frame:
Baseline and Week 12
Reported as:
Number · participants
Investigator Evaluations of Electrocardiogram (ECG) Results
participantsFluticasone Propionate/Salmeterol HFAFluticasone Propionate HFA
Baseline - Normal145155
Baseline - Abnormal: Not Clinically Significant2721
Baseline - Abnormal: Clinically Significant10
Week 12-No Change or insignificant Change136142
Week 12-Clinically Significant Change-Favorable20
Week 12-Clinically Significant Change-Unfavorable2418
PD-No Change or insignificant Change79
PD-Clinically Significant Change-Favorable01
PD-Clinically Significant Change-Unfavorable01
PrimaryClinically Significant Unfavorable ECGs at Week 12

Post-randomization ECGs categorized by the primary investigator as no change, significant change (favorable), significant change (unfavorable) from the ECG performed at Visit 1 (Baseline) are presented. Significant change (favorable) includes any ECG that improved from baseline, whereas significant change (unfavorable) includes any ECG that worsened from baseline. Clinical significance is determined by the primary investigator.

Time frame:
Baseline, Week 12
Reported as:
Number · participants
Clinically Significant Unfavorable ECGs at Week 12
participantsFluticasone Propionate/Salmeterol HFAFluticasone Propionate HFA
Clinically significant unfavorable change2418
AEs Reported for ECG findings2218
Clinically significant unfavorable ECGs repeated1111
Repeated ECGs w/ no change or insignificant change65
PrimaryECG Measures - Heart Rate

The range of heart rates for this study was between 49-144 beats per minute

Time frame:
Baseline and Week 12
Reported as:
Mean · beats per minute
ECG Measures - Heart Rate
beats per minuteFluticasone Propionate/Salmeterol HFAFluticasone Propionate HFA
Mean Heart Rate - Baseline84 (53 to 144)82.6 (51 to 136)
Mean Heart Rate - Week 1285.5 (59 to 138)81.9 (52 to 121)
Mean Heart Rate - Premature Discontinuation73.1 (53 to 90)92.4 (49 to 130)
PrimaryECG Measures - QT Interval

Fridericia's formula QTc interval=QT interval/cubed root of the R-R interval. The Bazett's formula QTc=QT/squared root of the R-R interval.

Time frame:
Baseline and Week 12
Reported as:
Mean · milliseconds
ECG Measures - QT Interval
millisecondsFluticasone Propionate/Salmeterol HFAFluticasone Propionate HFA
Mean QTc Interval (Fridericia)- Baseline394.5 (340 to 449)390.8 (338 to 429)
Mean QTc Interval (Fridericia) - Week 12397.5 (355 to 439)393.6 (329 to 449)
Premature Discontinuation (Fridericia)392 (359 to 417)394.8 (376 to 408)
Mean QTc Interval (Bazett) - Baseline416.3 (356 to 464)411.4 (346 to 471)
Mean QTc Interval (Bazett) - Week 12420.8 (368 to 466)413.7 (351 to 477)
Premature Discontinuation (Bazett)403.3 (376 to 446)422.7 (378 to 454)
PrimaryCardiovascular Adverse Events Reported During Treatment Period

Cardiovascular Adverse Events, as categorized by the Medical Dictionary for Regulatory Activities (MeDRA), reported during Treatment Period. The Adverse Events were identified in any ECG interpretation by a central reader (Cardiologist) for any ECG obtained after the first treatment dose and were then reported by the Primary Investigator as an Adverse Event. Please see the category titles for a list of candidate cardiovascular adverse events.

Time frame:
12-Week Treatment Period
Reported as:
Number · participants
Cardiovascular Adverse Events Reported During Treatment Period
participantsFluticasone Propionate/Salmeterol HFAFluticasone Propionate HFA
Participants with Any Event98103
Electrocardiogram (ECG) Change32
ECG QTc Interval Prolonged21
ECG Abnormal11
ECG QT Borderline Prolonged10
Defect Conduction Intraventricular43
Cardiac Arrhythmia10
Premature Atrial Contraction10
PrimaryCardiovascular Adverse Events Reported During the Post-Treatment Period

Cardiovascular Adverse Events, as categorized by the Medical Dictionary for Regulatory Activities (MeDRA), reported during Post-treatment period, defined as 1 day after last dose of study drug. The Adverse Events were identified in any ECG interpretation by a central reader (Cardiologist) for any ECG obtained after the first treatment dose and were then reported by the Primary Investigator as an Adverse Event.

Time frame:
5 Days after Week 12
Reported as:
Number · participants
Cardiovascular Adverse Events Reported During the Post-Treatment Period
participantsFluticasone Propionate/Salmeterol HFAFluticasone Propionate HFA
Participants with Any Event1919
ECG QTc interval prolonged115
QT interval prolonged12
ECG QT interval Abnormal10
Defect Conduction Intraventricular27
Conduction disorder11
Sinus Tachycardia10
Supraventricular Ectopics01
PrimaryAsthma Exacerbations: Worsening of Asthma Requiring Emergency Intervention, Hospitalization, or Treatment With Asthma Medications Prohibited by the Protocols

The Primary Investigator determined the severity of the exacerbation based on the participant's clinical presentation and the investigator's understanding of the disease, the participant, and his or her clinical experiences. The severity of the exacerbation was not defined in the protocol. Mild: Usually treated at home. Prompt relief with inhaled short-acting beta2 agonist. Possible short course of oral systemic corticosteroids. Moderate: Usually requires office or emergency department visit. Relief with frequent inhaled short-acting beta2 agonist. Oral systemic corticosteroids; some symptoms last for 1-2 days after treatment begins. Severe: Usually requires emergency department visit and likely hospitalization. Partial relief with frequent inhaled short-acting beta2 agonist. Oral systemic corticosteroids; some symptoms last for more than 3 days after treatment begins. Adjunctive therapies are helpful.

Time frame:
Treatment period (weeks 1-12)
Reported as:
Number · participants
Asthma Exacerbations: Worsening of Asthma Requiring Emergency Intervention, Hospitalization, or Treatment With Asthma Medications Prohibited by the Protocols
participantsFluticasone Propionate/Salmeterol HFAFluticasone Propionate HFA
Participants with any asthma exacerbation13
Severity - Mild12
Severity - Moderate/Severe01
Withdrawal due to Asthma Exacerbation12
PrimaryNumber of Participants With the Indicated Levels of 24-hour Urinary Cortisol Excretion

"Abnormal high cortisol excretion" and "Abnormal low cortisol excretion" are defined as above the upper limit of normal and below the lower limit of normal, respectively. The normal range for cortisol levels vary by age and gender. An abnormality is defined as a value of 24-hour urinary cortisol excretion that is outside the normal range. The normal range for 24-hour urinary cortisol excretion was provided by the central laboratory.

Time frame:
Baseline and week 12
Reported as:
Number · participants
Number of Participants With the Indicated Levels of 24-hour Urinary Cortisol Excretion
participantsFluticasone Propionate/Salmeterol HFAFluticasone Propionate HFA
Baseline - Abnormal high cortisol excretion, n1317
Baseline - Abnormal low cortisol excretion, n10
Week 12 - Abnormal high cortisol excretion, n138
Week 12 - Abnormal low cortisol excretion, n20
PrimaryGeometric Mean Values of 24-hour Urinary Cortisol Excretion at Baseline and Week 12

Normal range for Cortisol levels vary by age and gender. Geometric mean is the product of the values taken to the Nth root, where N is the number of values in the set of values.

Time frame:
Baseline and Week 12
Reported as:
Geometric mean · Nanomoles per 24 hours (nmol/24 hrs)
Geometric Mean Values of 24-hour Urinary Cortisol Excretion at Baseline and Week 12
Nanomoles per 24 hours (nmol/24 hrs)Fluticasone Propionate/Salmeterol HFAFluticasone Propionate HFA
Baseline - Geometric Mean32.71 (2.7 to 156.2)30.88 (4.2 to 891.6)
Week 12 - Geometric Mean25.03 (1.7 to 152.6)23.17 (5.3 to 145.8)
PrimaryGeometric Mean Ratio for Week12:Baseline for 24-hour Urinary Cortisol Excretion

Normal range for Cortisol levels vary by age and gender. The data provided are a direct calculation of the Week 12 geometric mean divided by the baseline value, nanomoles per 24 hours (nmol/24 hrs).

Time frame:
Baseline and Week 12
Reported as:
Number · ratio
Geometric Mean Ratio for Week12:Baseline for 24-hour Urinary Cortisol Excretion
ratioFluticasone Propionate/Salmeterol HFAFluticasone Propionate HFA
Geometric Mean Ratio for Week12:Baseline for 24-hour Urinary Cortisol Excretion0.770.75
PrimaryNumber of Participants With the Indicated Levels of 24 Hour Urinary Cortisol Excretion by Spacer Use

AeroChamber Plus spacers were provided for participants who demonstrated the inability to coordinate the use of an Meter Dose Inhaler at Visit 1. AeroChamber Plus spacer delivers 22% more medication than the original AeroChamber and is available in three mask sizes and without a mask. "Abnormal high cortisol excretion" and "Abnormal low cortisol excretion" are defined as above the upper limit of normal and below the lower limit of normal, respectively. An abnormality is defined as a value of 24-hour urinary cortisol excretion that is outside the normal range. The normal range for 24-hour urinary cortisol excretion was provided by the central laboratory.

Time frame:
Baseline and Week 12
Reported as:
Number · participants
Number of Participants With the Indicated Levels of 24 Hour Urinary Cortisol Excretion by Spacer Use
participantsFluticasone Propionate/Salmeterol HFA - SpacerFluticasone Propionate/Salmeterol HFA - No SpacerFluticasone Propionate HFA - SpacerFluticasone Propionate HFA - No Spacer
Baseline - Abnormal high cortisol excretion121143
Baseline - Abnormal low cortisol excretion0100
Week 12 - Abnormal high cortisol excretion10371
Week 12 - Abnormal low cortisol excretion2000
PrimaryGeometric Mean Values of 24 Hour Urinary Cortisol Excretion by Spacer Use at Baseline and Week 12

AeroChamber Plus spacers were provided for participants who demonstrated the inability to coordinate the use of an Meter Dose Inhaler at Visit 1. AeroChamber Plus spacer delivers 22% more medication than the original AeroChamber and is available in three mask sizes and without a mask. Geometric mean is the product of the values taken to the Nth root, where N is the number of values in the set of values.

Time frame:
Baseline and Week 12
Reported as:
Geometric mean · Nanomoles per 24 hours (nmol/24 hrs)
Geometric Mean Values of 24 Hour Urinary Cortisol Excretion by Spacer Use at Baseline and Week 12
Nanomoles per 24 hours (nmol/24 hrs)Fluticasone Propionate/Salmeterol HFA - SpacerFluticasone Propionate/Salmeterol HFA - No SpacerFluticasone Propionate HFA - SpacerFluticasone Propionate HFA - No Spacer
Baseline - Geometric Mean31.89 (3.6 to 156.2)35.84 (2.7 to 143.3)30.61 (4.2 to 891.6)31.89 (7.9 to 335.0)
Week 12 - Geometric Mean23.37 (1.7 to 143.3)32.05 (4.6 to 152.6)23.20 (5.3 to 103.2)23.06 (5.4 to 145.8)
PrimaryGeometric Mean Ratio for Week12: Baseline for 24 Hour Urinary Cortisol Excretion by Spacer Use

AeroChamber Plus spacers were provided for participants who demonstrated the inability to coordinate the use of an Meter Dose Inhaler at Visit 1. AeroChamber Plus spacer delivers 22% more medication than the original AeroChamber and is available in three mask sizes and without a mask. The data provided are a direct calculation of the Week 12 geometric mean divided by the baseline value, nanomoles per 24 hours (nmol/24 hrs).

Time frame:
Baseline and Week 12
Reported as:
Number · ratio
Geometric Mean Ratio for Week12: Baseline for 24 Hour Urinary Cortisol Excretion by Spacer Use
ratioFluticasone Propionate/Salmeterol HFA - SpacerFluticasone Propionate/Salmeterol HFA - No SpacerFluticasone Propionate HFA - SpacerFluticasone Propionate HFA - No Spacer
Geometric Mean Ratio for Week12: Baseline for 24 Hour Urinary Cortisol Excretion by Spacer Use0.730.890.760.72
SecondaryClinic Morning (AM) Forced Expiratory Volume in Participants 6-11 Years

FEV1 (Forced Expiratory Volume in 1 second) is the volume of air that can be forced out in one second, after taking a deep breath. FEV1 is measured using a spirometer and obtaining "best effort" from 3 to 8 measurements. Week 12 is the measure taken at Week 12.

Time frame:
Baseline and week 12
Reported as:
Mean · Liters per second (L/sec)
Clinic Morning (AM) Forced Expiratory Volume in Participants 6-11 Years
Liters per second (L/sec)Fluticasone Propionate/Salmeterol HFAFluticasone Propionate HFA
Baseline - Mean FEV11.67 ± 0.0351.64 ± 0.035
Week 12 - Mean FEV11.91 ± 0.0381.82 ± 0.036
Week 12 - Mean Change from baseline0.24 ± 0.0230.18 ± 0.023
Premature discontinuation - Mean FEV11.81 ± 0.141.70 ± 0.212
Premature discontin. - Mean Change from baseline0.03 ± 0.09-0.07 ± 0.120
SecondaryAM Peak Expiratory Flow

The peak expiratory flow (PEF) rate measures how fast a person can exhale air. It is used to compare to normal flow rates to predict obstruction and disease. The average PEF for a child or adolescent whose height is 43 inches is 147 Liters/minute (L/min), whose height is 66 inches is 454 L/min. Triplicate measurements taken for the best effort recorded.

Time frame:
Baseline and 12-Week Treatment Period
Reported as:
Mean · Liters/minute (L/min)
AM Peak Expiratory Flow
Liters/minute (L/min)Fluticasone Propionate/Salmeterol HFAFluticasone Propionate HFA
Baseline - Mean AM PEF213 ± 4.83203 ± 4.37
Weeks 1-12 - Mean AM PEF233 ± 5.07220 ± 4.43
Weeks 1-12 - Mean Change from Baseline20.2 ± 2.0417.4 ± 1.86
Last 7 Days on Treatment - Mean AM PEF238 ± 5.39226 ± 4.73
Last 7 Days on Treatment-Mean Change from Baseline25.3 ± 2.5823.3 ± 2.47
SecondaryAsthma Symptom Scores

Each morning prior dosing or PEF, self-scored based on past 24 hours: 0=No symptoms, 1=Symptoms for one short period, 2=Symptoms for two or more short periods, 3=Frequent Symptoms which did not affect activities of daily living (ADL), 4=Frequent.

Time frame:
Baseline and 12-Week Treatment Period
Reported as:
Mean · Score in scale
Asthma Symptom Scores
Score in scaleFluticasone Propionate/Salmeterol HFAFluticasone Propionate HFA
Baseline - Mean Score1.3 ± 0.061.4 ± 0.06
Weeks 1-12 - Mean Score0.9 ± 0.060.8 ± 0.05
Weeks 1-12 - Mean change from baseline-0.4 ± 0.06-0.6 ± 0.06
Last 7 Days on Treatment - Mean Score0.8 ± 0.070.8 ± 0.07
Last 7 Days on Treat. - Mean change from baseline-0.5 ± 0.07-0.6 ± 0.08
SecondaryPercentage of Symptom Free Days

Percentage of number of days without asthma symptoms based on Asthma Symptom Scores. Each morning prior to dosing or PEF, asthma symptoms were self-scored based on the past 24 hours: 0=no symptoms, 1=symptoms for one short period, 2=symptoms for two or more short periods, 3=frequent symptoms that did not affect activities of daily living (ADL), 4=frequent .

Time frame:
Baseline and 12-Week Treatment Period
Reported as:
Mean · Percentage of days
Percentage of Symptom Free Days
Percentage of daysFluticasone Propionate/Salmeterol HFAFluticasone Propionate HFA
Baseline - Mean Percent20.0 ± 2.0218.4 ± 2.00
Weeks 1-12 - Mean Percent46.7 ± 2.7748.7 ± 2.80
Weeks 1-12 - Mean change from baseline26.8 ± 2.4730.5 ± 2.62
Last 7 Days on Treatment - Mean Percent51.9 ± 3.5153.4 ± 3.44
Last 7 Days on Treat. - Mean change from baseline32.1 ± 3.3234.9 ± 3.43
SecondaryAlbuterol Use

Albuterol inhalation aerosol was used as a rescue or prophylactic and recorded daily by subject or caregiver. The number of puffs of albuterol over the previous 24 hour period prior to dosing was recorded.

Time frame:
Baseline and 12-Week Treatment Period
Reported as:
Mean · Number of puffs per 24 hours
Albuterol Use
Number of puffs per 24 hoursFluticasone Propionate/Salmeterol HFAFluticasone Propionate HFA
Baseline - Mean number of puffs1.5 ± 0.121.8 ± 0.19
Weeks 1-12 - Mean number of puffs1.0 ± 0.090.9 ± 0.09
Weeks 1-12 - Mean change from baseline-0.6 ± 0.12-1.0 ± 0.16
Last 7 Days on Treatment - Mean number of puffs0.7 ± 0.110.7 ± 0.11
Last 7 Days on Treat. - Mean change from baseline0.15 ± 0.8-1.2 ± 0.19
SecondaryPercent of Albuterol-free Days

Percentage of days when Albuterol use was unnecessary based on daily record and symptom free days.

Time frame:
Baseline and 12-Week Treatment Period
Reported as:
Mean · Percentage of days
Percent of Albuterol-free Days
Percentage of daysFluticasone Propionate/Salmeterol HFAFluticasone Propionate HFA
Baseline - Mean percent rescue free43.7 ± 2.8542.5 ± 3.04
Weeks 1-12 - Mean percent rescue free67.1 ± 2.4670.0 ± 2.40
Weeks 1-12 - Mean change from baseline23.6 ± 2.7928.3 ± 2.93
Last 7 Days on Treat. - Mean percent rescue free75.4 ± 2.9675.8 ± 2.98
Last 7 Days on Treat. - Mean change from baseline30.4 ± 3.5032.8 ± 3.58
Post-hocGeometric Mean Values of 24-hour Urinary Cortisol Excretion at Baseline and Week 12

A post-hoc analysis excluding participants with urine cortisol baseline values of \>200 nanomoles/24 hours. Geometric mean is the product of the values taken to the Nth root, where N is the number of values in the set of values.

Time frame:
Baseline and Week 12
Reported as:
Geometric mean · Nanamoles per 24 hours (nmol/24 hrs)
Geometric Mean Values of 24-hour Urinary Cortisol Excretion at Baseline and Week 12
Nanamoles per 24 hours (nmol/24 hrs)Fluticasone Propionate/Salmeterol HFAFluticasone Propionate HFA
Baseline - Geometric Mean32.71 (2.7 to 156.2)28.39 (4.2 to 146.9)
Week 12 - Geometric Mean25.03 (1.7 to 152.6)22.80 (5.3 to 145.8)
Post-hocGeometric Mean Ratio for Baseline:Week12 24-hour Urinary Cortisol Excretion

A post-hoc analysis excluding participants with urine cortisol baseline values of \>200 nmol/24 hrs. The data provided are a direct calculation of the Week 12 geometric mean divided by the baseline value, nanomoles per 24 hours (nmol/24 hrs) .

Time frame:
Baseline and Week 12
Reported as:
Number · ratio
Geometric Mean Ratio for Baseline:Week12 24-hour Urinary Cortisol Excretion
ratioFluticasone Propionate/Salmeterol HFAFluticasone Propionate HFA
Geometric Mean Ratio for Baseline:Week12 24-hour Urinary Cortisol Excretion0.770.80
Post-hocGeometric Mean Values of 24-hour Urinary Cortisol Excretion by Spacer Use Excluding Participants With Abnormal Urinary Cortisol Excretion Values at Baseline From the Cortisol Population at Baseline and Week 12

AeroChamber Plus spacers were provided for participants who demonstrated the inability to coordinate the use of an Meter Dose Inhaler at Visit 1. AeroChamber Plus spacer delivers 22% more medication than the original AeroChamber and is available in three mask sizes and without a mask. Geometric mean is the product of the values taken to the Nth root, where N is the number of values in the set of values.

Time frame:
Baseline and Week 12
Reported as:
Geometric mean · Nanomoles per 24 hr (nmoles/24 hr)
Geometric Mean Values of 24-hour Urinary Cortisol Excretion by Spacer Use Excluding Participants With Abnormal Urinary Cortisol Excretion Values at Baseline From the Cortisol Population at Baseline and Week 12
Nanomoles per 24 hr (nmoles/24 hr)No SpacerSpacer
Baseline - Geometric Mean31.88 (7.9 to 81.7)27.08 (3.6 to 166.3)
Week 12 - Geometric Mean27.85 (5.4 to 152.6)22.38 (1.7 to 143.3)
Post-hocGeometric Mean Ratio for Baseline: Week 12 24-hour Urinary Cortisol Excretion by Spacer Use Excluding Participants With Abnormal Urinary Cortisol Excretion Values at Baseline From the Cortisol Population

AeroChamber Plus spacers were provided for participants who demonstrated the inability to coordinate the use of an Meter Dose Inhaler at Visit 1. AeroChamber Plus spacer delivers 22% more medication than the original AeroChamber and is available in three mask sizes and without a mask. The data provided are a direct calculation of the Week 12 geometric mean divided by the baseline value,nanomoles per 24 hours (nmol/24 hrs) .

Time frame:
Baseline and Week 12
Reported as:
Number · ratio
Geometric Mean Ratio for Baseline: Week 12 24-hour Urinary Cortisol Excretion by Spacer Use Excluding Participants With Abnormal Urinary Cortisol Excretion Values at Baseline From the Cortisol Population
ratioSpacerNo Spacer
Geometric Mean Ratio for Baseline: Week 12 24-hour Urinary Cortisol Excretion by Spacer Use Excluding Participants With Abnormal Urinary Cortisol Excretion Values at Baseline From the Cortisol Population0.870.83

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Fluticasone Propionate/Salmeterol HFA—1/173 (0.6%)61/173 (35.3%)
Fluticasone Propionate HFA—0/177 (0%)68/177 (38.4%)
Most frequent serious events
Most frequent serious events
EventFluticasone Propionate/Salmeterol HFAFluticasone Propionate HFA
Head Injury due to fallInjury, poisoning and procedural complications1/1730/177
Most frequent other events
Most frequent other events
EventFluticasone Propionate/Salmeterol HFAFluticasone Propionate HFA
HeadacheNervous system disorders26/17325/177
NasopharyngitisInfections and infestations16/17321/177
PyrexiaGeneral disorders8/17316/177
Upper Respiratory Tract InfectionInfections and infestations11/17313/177
PharyngitisInfections and infestations4/17312/177
CoughRespiratory, thoracic and mediastinal disorders9/1737/177
RhinitisInfections and infestations8/1736/177

Baseline characteristics

Age, Customized
Age, Customized(participants)Fluticasone Propionate/Salmeterol HFAFluticasone Propionate HFATotal
4-5 years364177
6-11 years137136273
Gender
Gender(Participants)Fluticasone Propionate/Salmeterol HFAFluticasone Propionate HFATotal
Female6671137
Male107106213
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Fluticasone Propionate/Salmeterol HFAFluticasone Propionate HFATotal
Hispanic or Latino7073143
Not Hispanic or Latino103104207
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Fluticasone Propionate/Salmeterol HFAFluticasone Propionate HFATotal
White/Caucasian/European Heritage114113227
American Indian or Alaska Native242751
Central/South Asian Heritage8816
African American/African Heritage7815
Japanese Heritage303
Arabic/North African Heritage224
South East Asian Heritage202
Mixed Race131932
08

Study locations

55 sites
  • GSK Investigational Site
    Huntington Beach, California 92647, United States
  • GSK Investigational Site
    Long Beach, California 90806, United States
  • GSK Investigational Site
    Long Beach, California 90808, United States
  • GSK Investigational Site
    Riverside, California 92506, United States
  • GSK Investigational Site
    Denver, Colorado 80206, United States
  • GSK Investigational Site
    Lakewood, Colorado 80401, United States
  • GSK Investigational Site
    Jacksonville, Florida 32207, United States
  • GSK Investigational Site
    Gainesville, Georgia 30501, United States
  • GSK Investigational Site
    Ypsilanti, Michigan 48197, United States
  • GSK Investigational Site
    Cortland, New York 14850, United States
  • GSK Investigational Site
    Raleigh, North Carolina 27607, United States
  • GSK Investigational Site
    Canton, Ohio 44718, United States
  • GSK Investigational Site
    Oklahoma City, Oklahoma 73120, United States
  • GSK Investigational Site
    Lake Oswego, Oregon 97035, United States
  • GSK Investigational Site
    Medford, Oregon 97504, United States
  • GSK Investigational Site
    Portland, Oregon 97213, United States
  • GSK Investigational Site
    Pittsburgh, Pennsylvania 15241, United States
  • GSK Investigational Site
    Charleston, South Carolina 29407, United States
  • GSK Investigational Site
    Germantown, Tennessee 38138, United States
  • GSK Investigational Site
    South Burlington, Vermont 05403, United States
  • GSK Investigational Site
    Clayton, Victoria 3168, Australia
  • GSK Investigational Site
    Parkville, Victoria 3052, Australia
  • GSK Investigational Site
    Subiaco, Western Australia 6001, Australia
  • GSK Investigational Site
    St. John's, Newfoundland and Labrador A1E 2C2, Canada
  • GSK Investigational Site
    Brampton, Ontario L6T 3T1, Canada
  • GSK Investigational Site
    Mississauga, Ontario L5A 3V4, Canada
  • GSK Investigational Site
    Sarnia, Ontario N7T 4X3, Canada
  • GSK Investigational Site
    Santiago, Región Metro De Santiago, Chile
  • GSK Investigational Site
    Viña del Mar, Valparaíso, Chile
  • GSK Investigational Site
    Santiago, 8360156, Chile
  • GSK Investigational Site
    San Jose, Costa Rica
  • GSK Investigational Site
    Bochum, Nordrhein-Westfalen 44791, Germany
  • GSK Investigational Site
    Guetersloh, Nordrhein-Westfalen 33332, Germany
  • GSK Investigational Site
    Kleve-Materborn, Nordrhein-Westfalen 47533, Germany
  • GSK Investigational Site
    Wesel, Nordrhein-Westfalen 46483, Germany
  • GSK Investigational Site
    Mainz, Rheinland-Pfalz 55131, Germany
  • GSK Investigational Site
    Geesthacht, Schleswig-Holstein 21502, Germany
  • GSK Investigational Site
    Ogre, LV5001, Latvia
  • GSK Investigational Site
    Riga, LV1050, Latvia
  • GSK Investigational Site
    Kaunas, LT-50009, Lithuania
  • GSK Investigational Site
    Utena, LT-28151, Lithuania
  • GSK Investigational Site
    Vilnius, LT-01117, Lithuania
  • GSK Investigational Site
    Monterrey N.L, Nuevo León 64988, Mexico
  • GSK Investigational Site
    Chihuahua, 31020, Mexico
  • GSK Investigational Site
    Mexico city, 04530, Mexico
  • GSK Investigational Site
    Mexico, 6720, Mexico
  • GSK Investigational Site
    Lima, Lima 27, Peru
  • GSK Investigational Site
    Lodz, 90-329, Poland
  • GSK Investigational Site
    Rabka, 34-700, Poland
  • GSK Investigational Site
    Moscow, 119435, Russian Federation
  • GSK Investigational Site
    Novosibirsk, 630099, Russian Federation
  • GSK Investigational Site
    St'Petersburg, 191144, Russian Federation
  • GSK Investigational Site
    Tomsk, 634 050, Russian Federation
  • GSK Investigational Site
    Murcia, 30120, Spain
  • GSK Investigational Site
    San Javier (Murcia), 30720, Spain
09

References and documents

Publications

  • Li JS, Qaqundah PY, Weinstein SF, LaForce CF, Ellsworth AV, Ortega HG, Ferro TJ. Fluticasone propionate/salmeterol combination in children with asthma: key cardiac and overall safety results. Clin Res Reg Affairs 2010;27(3):87-95.

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2007, a primary completion of Jan 2008 and a completion of Jan 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2010, 2 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 28, 2007
First posted
Mar 1, 2007
Start
Feb 2007
Primary completionActual
Jan 2008
CompletionActual
Jan 2008
Results first posted
Sep 23, 2010
Last update
Dec 16, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 16, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00441441
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Mar 1, 2007
Start date
Feb 2007
Primary completion
Jan 2008
Completion
Jan 2008
Results posted
Sep 23, 2010
Last update
Dec 16, 2016

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fluticasone · Salmeterol Xinafoate

Start the discussion